Cohance Life (COHANCE)

FairStock Score: 44/100 — MIXED

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Low debt: Debt/Equity of 0.12 and Altman Z-Score of 4.32 indicate a financially stable balance sheet.
• Promoter holding of 57.49% aligns management with minority shareholders.
• ROE of 16.51% and ROCE of 14.89% show decent capital efficiency despite the recent profit drop.
• Latest quarter sales of ₹545 Cr and 23.20% sales growth show demand momentum.

Concerns

• Profit growth of -33.35% with net profit of just ₹29 Cr on ₹545 Cr sales shows severe margin compression.
• Valuation is rich: P/E 39.43, EV/EBITDA 41.32, and PEG 2.56; Graham Number ₹104.77 implies a -195.85% margin of safety.
• Free cash flow of ₹35 Cr is negligible against ₹11,858 Cr market cap, and DCF intrinsic value is ₹0.28; no dividend either.
• 5-year revenue CAGR of only 3.47% does not support a high-growth multiple despite the recent quarterly sales bump.

AI Analysis

Reading Cohance, I am reminded that a wonderful business can be a terrible investment at a high price. The company has some qualities I respect: debt-equity of 0.12, promoter holding of 57.49%, and an Altman Z-score of 4.32, so there is no near-term solvency worry. Return on equity of 16.51% and ROCE of 14.89% are respectable, though not exceptional. But the longer I look, the more the valuation disturbs me. The price of ₹363.85 gives a P/E of 39.43 on falling earnings. Profit growth is -33.35%, while sales grew 23.20%. That tells me margins are being squeezed and the market is paying a rich multiple for a business whose profits are going backwards. A Graham disciple would compare price with the Graham Number of ₹104.77. At more than three times that number, the margin of safety is negative at -195.85%. EV/EBITDA of 41.32 and free cash flow of only ₹35 Cr against a market capitalisation of ₹11,858 Cr reinforce the same conclusion: Mr Market is paying for a perfect future. The DCF value of ₹0.28 is extreme, but even if I discard it, cash generation is tiny relative to the asking price. The 5-year revenue CAGR of 3.47% does not justify a growth-stock multiple. I also notice the stock has fallen from ₹1,038.90 to ₹363.85. That may tempt a bottom-fisher, but a falling price is not a buffer. With no dividend and negative profit growth, this is not an income or compounding machine. It must prove it can turn revenue growth into profit. Until then, the margin of safety is absent. As Buffett says, it is far better to buy a wonderful company at a fair price; this is not a wonderful company at a fair price. I will wait.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer